Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial.
In a double-blind controlled clinical trial on 51 patients with subarachnoid hemorrhage, tranexamic acid, 4 gm per day for ten consecutive days, did not favorably affect the outcome. Neither mortality nor rebleeding rates were improved after a follow-up of three months.